Skip to main content Skip to search Skip to main navigation

FDA: Janet Woodcock becomes acting commissioner

Dr. Janet Woodcock has been appointed as acting commissioner of the FDA. The previous commissioner, Dr. Stephen M. Hahn, stepped down from his role at the start of President Biden's term of office.

Janet Woodcock already has a 30-year career at FDA. Most recently, she led the CDER (US FDA Center for Drug Evaluation and Research). Since May 2020, she has also been responsible for leading Operation Warp Speed to support the development of COVID-19 therapeutics. Woodcock will continue to perform this function.  

As she says, she welcomes the challenge of leading FDA on a transitional basis because: 

"The FDA’s public health work is more critical than ever as we continue to fight this global pandemic." 


Sources:

FDA: Janet Woodcock 

Twitter: Janet Woodcock 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

What is a gas?

What is a gas?

You can view the answer here:
Read more
EMA: Pilot Programme for Breakthrough Devices

EMA: Pilot Programme for Breakthrough Devices

The EMA plans to launch a pilot programme in Q2 2026 to implement the guidance for breakthrough devices issued in December 2025.

Read more
EDQM: New Ph. Eur. Chapter on Data Quality with a Focus on Digital Data

EDQM: New Ph. Eur. Chapter on Data Quality with a Focus on Digital Data

The European Pharmacopoeia (Ph. Eur.) has introduced a new general chapter that provides a framework for managing the quality of data, including digital data, throughout its life cycle.

Read more
PIC/S: Jordan FDA Joins PIC/S

PIC/S: Jordan FDA Joins PIC/S

On 1 January 2026, the Jordan Food & Drug Administration (JFDA) became the 57th PIC/S Participating Authority.

Read more
Swissmedic: Scientific GMDP Meetings

Swissmedic: Scientific GMDP Meetings

Swissmedic offers companies holding or seeking a Swissmedic manufacturing or distribution license the opportunity to discuss project-specific GMP and GDP topics in Scientific GMDP Meetings.

Read more
Purified Water – The new Chinese Pharmacopoeias and What Happens Next?

Purified Water – The new Chinese Pharmacopoeias and What Happens Next?

A new Chinese Pharmacopoeia was published in 2025. This has some significant implications for the pharmaceutical water industry, which we will discuss in more detail in this article. Firstly, it is important to note that cold WFI systems are now permitted worldwide and can be used across the board.
Read more
Previous
Next